Angiogenesis inhibition in non-GIST soft tissue sarcomas

Oncologist

Volumn 13, Issue 11, 2008, Pages 1193-1200

  Sleijfer, Stefan ^a   Van Der Graaf, Winette T A ^b   Blay, Jean Yves ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

Angiogenesis; Soft tissue sarcoma; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; DOXORUBICIN; GELATINASE A; GELATINASE B; IFOSFAMIDE; IMATINIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RAZOXANE; SORAFENIB; SUNITINIB; THALIDOMIDE; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEART EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOPIGMENTATION; LIVER TOXICITY; NONGASTROINTESTINAL STROMAL TUMOR; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56749170762     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0188     Document Type: Review

References (41)

1. Fletcher CDM, Uni KK, Mertnes F, eds. Pathology and Genetics of Tumors of Soft Tissue and Bone. WHO Classification of Tumours. Lyon, France: ARC Press, 2002:1-172.
2. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. The Oncologist 2005;10:833-841.
3. Tascilar M, Loos WJ, Seynaeve C et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. The Oncologist 2007;12:1351-1360.
4. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-819.
5. Pakos EE, Goussia AC, Tsekeris PG et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 2005;25:3591-3596.
6. Chao C, Al-Saleem T, Brooks JJ et al. Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlated with grade. Ann Surg Oncol 2001;8:260-267.
7. Yudoh K, Kanamori M, Ohmori K et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84:1610-1615.
8. Graeven U, Andre N, Achilles E et al. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999;125:577-581.
9. Feldman AL, Pak H, Yang JC et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001;91:1525-1529.
10. Hayes AJ, Mostyn-Jones A, Koban MU et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surgery 2004;91:242-247.
11. Yoon SS, Segal NH, Olshen AB et al. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol 2004;15:1261-1266.
12. Yoon SS, Segal NH, Park PJ et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006;135:282-290.
13. Kuhnen C, Lehnhardt M, Tolnay E et al. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J Cancer Res Clin Oncol 2000;126:219-225.
14. Potti A, Ganti AK, Tendulkar K et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 2004;130:52-56.
15. Itakura E, Yamamoto H, Oda Y et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008;97:74-81.
16. Wang J, Coltrera MD, Gown AM. Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: An immunohistochemical and in situ hybridization assay. Cancer Res 1994;560-564.
17. Lazar AJF, Das P, Tuvin D et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007;13:7314-7321.
18. Benassi MS, Gamberi G, Magagnoli G et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 2001;12:75-80.
19. Choong PFM, Fernö M, Akerman M et al. Urokinase-plasminogen- activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996;69:268-272.
20. Ch'ng E, Tomita Y, Zhang B et al. Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 2007;110:164-172.
21. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 2004;10:1344-1353.
22. Shintani K, Matsumine A, Kusuzaki K et al. Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch 2006;449:673-681.
23. Chawla AP, Tolcher AW, Staddon AP et al. Updated results of phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas. J Clin Oncol 2006;24:9505.
24. Zhang L, Hannay JA, Liu J et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: Implications for tumor growth, metastasis, and chemoresistance. Cancer Res 2006;66:8770-8778.
25. Dias S, Shmelkov SV, Lam G et al. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99:2532-2540.
26. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002;99:4349-4354.
27. Heldin CH, Rubin K, Pietras K et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-813.
28. Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: The resurrection of an old drug. Eur J Cancer 2004;40:2377-2382.
29. Yi-Shin Kuo D, Timmins P, Blank SV et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: A brief communication from the New York Phase II consortium. Gynecol Oncol 2006;100:160-165.
30. Raina V, Sengar M, Shukla NK et al. Complete response from thalidomide in angiosarcoma after treatment of breast cancer. J Clin Oncol 2007;25:900-901.
31. Ryan CW, Von Mehren M, Rankin CJ et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008;26(suppl):561.
32. Maki RG, Keohan ML, Undevia M et al. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060. J Clin Oncol 2008;26(suppl):560.
33. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
34. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
35. Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
36. Van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549.
37. Keohan ML, Morgan JA, D'Adamo DR et al. Continuous daily dosing (CCD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. J Clin Oncol 2008;26(suppl):501.
38. Vigil CE, Chiaporri AA, Williams CA et al. Phase II of sunitinib malate (SM) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II study. J Clin Oncol 2008;26(suppl): Abstract 10535.
39. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a phase II study from the EORTC STBSG (EORTC 62043). Proc Connec Tissue Oncol Soc 2007:13;12.
40. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142.
41. Heist RS, Zhai R, Liu G et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-862.